01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

Open Orphan Chairman Cathal Friel speaks to BRR Media re the new contract, other developments and the CEO’s departure May 5, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan PLC’s (LON:ORPH) Cathal Friel speaks to Rosie Riall at BRR Media after signing a new deal with a US biotech for the provision of a respiratory syncytial virus human challenge study. Cathal also covers the channel pipeline, the hVIVO quarantine centre, flu and malaria vaccines and the planned departure of CEO Trevor Phillips.

Continue reading

Open Orphan: Flu vaccine data showcased in peer reviewed article – Proactive Investors April 17, 2020 – Posted in: Open Orphan (ORPH)

by Ian Lyall.  FLU-v has been developed by Imutex, 49%-owned by Open Orphan unit hVIVO The results of a successful phase IIb trial of a potential flu vaccine being developed by an Open Orphan PLC  (LON:ORPH) joint-venture have been written up in a peer-reviewed article carried by a scientific journal. The data from FLU-v 004 challenge study underlined its ability to reduce mild-to-moderate symptoms of the illness. FLU-v has been developed by Imutex, 49%-owned by…

Continue reading

Open Orphan #ORPH – Publication of positive FLU-v vaccine challenge study results in journal March 16, 2020 – Posted in: Open Orphan (ORPH)

Positive results from FLU-v vaccine challenge study (FLU-v 004), the second Phase IIb study of FLU-v, which has been developed by Imutex Limited, hVIVO’s 49% joint venture with the SEEK Group, have now been published in a peer review journal FLU-v is a first-in-class ‘universal’, broad spectrum, standalone, influenza vaccine candidate The publication in ‘npj Vaccines’ reported that one dose of FLU-v induced statistically significant reduction in mild to moderate influenza disease (MMID) defined as detection…

Continue reading

Proactive Investors – Open Orphan #ORPH catching global attention with ‘stunning’ FLU-v results & world-first coronavirus study – Posted in: Open Orphan (ORPH)

Open Orphan PLC‘s (LON:ORPH) Cathal Friel and its subsidiary hVIVO’s chief scientist Dr Andrew Catchpole sat down with Proactive London’s Andrew Scott. This morning Open Orphan announced the results from a clinical trial of a broad-spectrum flu jab that they’re jointly developing have been published in a peer-reviewed journal. The data from the FLU-v 003 phase IIb study of the FLU-v vaccine appeared in the Annals of Internal Medicine periodical. Also this week hVIVO began…

Continue reading

Open Orphan #ORPH – Publication of Positive Results in Journal March 10, 2020 – Posted in: Open Orphan (ORPH)

Positive results from Phase IIb field study of FLU-v vaccine (FLU-v 003), which has been developed by Imutex Limited, hVIVO’s 49% joint venture with the SEEK Group. FLU-v is a first-in-class ‘universal’, broad spectrum, standalone, influenza vaccine candidate and the results have now been published in a peer review journal The publication in the Annals of Internal Medicine journal concluded adjuvanted FLU-v is immunogenic and merits Phase III development to explore efficacy Compelling data package…

Continue reading